title: Liposomes containing NY‑ESO‑1/tetanus  toxoid and adjuvant peptides targeted to  human dendritic cells via the Fc receptor for  cancer vaccines.
abstract: OBJECTIVE
  To improve the immunological response against tumors, a vaccine based on nanoliposomes targeted to the Fcg-receptor was developed to enhance the immunogenicity of tumor-associated antigens (TAAs).
  
  
  METHODS
  Using human dendritic cells in vitro, a fragment of the TAA NY-ESO-1 combined with a T-helper peptide from the tetanus toxoid encapsulated in nanoliposomes was evaluated. In addition, peptides Palm-IL-1 and MAP-IFN-g were coadministered as adjuvants to enhance the immunological response.
  
  
  RESULTS
  Coadministration of Palm-IL-1 or MAP-IFN-g peptide adjuvants and the hybrid NY-ESO-1-tetanus toxoid (soluble or encapsulated in nanoliposomes without targeting) increased immunogenicity. However, the most potent immunological response was obtained when the peptide adjuvants were encapsulated in liposomes targeted to human dendritic cells via the Fc receptor.
  
  
  CONCLUSIONS
  This targeted vaccine strategy is a promising tool to activate and deliver antigens to dendritic cells, thus improving immunotherapeutic response in situations in which the immune system is frequently compromised, as in advanced cancers.
authors.forename: Luis J
authors.initials: LJ
authors.lastname: Cruz
authors.forename: Felix
authors.initials: F
authors.lastname: Rueda
authors.forename: Lorena
authors.initials: L
authors.lastname: Simón
authors.forename: Begoña
authors.initials: B
authors.lastname: Cordobilla
authors.forename: Fernando
authors.initials: F
authors.lastname: Albericio
authors.forename: Joan C
authors.initials: JC
authors.lastname: Domingo
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000494:pharmacology; D000951:Antigens, Neoplasm / Q000008:administration & dosage* / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000276:immunology; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000276:immunology*; D016503:Drug Delivery Systems; D006801:Humans; D008081:Liposomes / Q000276:immunology*; D008565:Membrane Proteins / Q000008:administration & dosage* / Q000276:immunology; D009369:Neoplasms / Q000276:immunology / Q000517:prevention & control; D010455:Peptides / Q000008:administration & dosage / Q000276:immunology; D017452:Receptors, IgG / Q000276:immunology*; D013745:Tetanus Toxoid / Q000008:administration & dosage* / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000951:Antigens, Neoplasm; C104948:CTAG1B protein, human; D019496:Cancer Vaccines; D008081:Liposomes; D008565:Membrane Proteins; D010455:Peptides; D017452:Receptors, IgG; D013745:Tetanus Toxoid